NASDAQ · Medical - Devices

IART (IART) Stock

$16.62 -1.77% NASDAQ: IART Healthcare

Valuation

MetricValue
Price$16.62
Market Cap$1.29B
P/E Ratio-183.51
P/B Ratio1.26
P/S Ratio0.80
EPS (TTM)$-6.73
52-Week High$20.49
52-Week Low$8.70
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-0.69%
ROA-0.20%
ROCE20.25%
Gross Margin53.21%
Operating Margin7.53%
Net Margin-0.44%
Debt/Equity1.94
Current Ratio2.54

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.5B$1.6B$1.5B$1.6B$1.6B
Operating Profit$197.0M$239.0M$112.0M$28.0M$68.0M
Net Profit$169.0M$181.0M$68.0M$-7.0M$-516.0M
EPS$1.98$2.16$0.84$-0.09$-6.73
Op Margin12.8%15.3%7.2%1.8%4.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$3.8B$3.9B$3.8B$4.0B$3.6B
Total Liabilities$2.1B$2.1B$2.2B$2.5B$2.6B
Cash$513.0M$457.0M$276.0M$246.0M$235.0M
Borrowings$1.7B$1.6B$1.7B$2.0B$2.0B

Latest News

Is This the Right Time to Hold MYGN Stock in Your Portfolio? Zacks · Jul 15, 2026 Why Integra LifeSciences (IART) Stock Is Up Today StockStory · Jul 9, 2026 Illumina Stock Gains 43.7% in 2026: What's Powering the Rally? Zacks · Jul 9, 2026 Integra (IART) Is Attractively Priced Despite Fast-paced Momentum Zacks · Jul 9, 2026 BMO Capital Initiates Integra LifeSciences at Market Perform With $19 Price Target MT Newswires · Jul 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$312.0M$264.0M$140.0M$129.0M$50.0M
Investing Cash Flow$-210.0M$-106.0M$-161.0M$-495.0M$-204.0M
Financing Cash Flow$-5.0M$-150.0M$-284.0M$-62.0M$-19.0M
Net Cash Flow$43.0M$-57.0M$-180.0M$-30.0M$-11.0M
Free Cash Flow$264.0M$217.0M$73.0M$25.0M$-45.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-1.83
EV / EBITDA12.62
FCF Yield2.95%
Quick Ratio1.98
Interest Coverage6.82
Return 1Y45.00%
Return 3Y-59.38%
Return 5Y-72.36%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BCAX $23.42 +1.30% -7.32 $1.54B 0.00%
BFLY $8.18 +3.68% -60.65 $2.18B 0.00%
EYPT $4.58 +1.78% -1.20 $383.99M 0.00%
FTRE $17.72 -3.54% -1.26 $1.69B 0.00%
INMD $15.03 +0.47% 9.72 $863.94M 0.00%

About IART

IART is led by CEO Mojdeh Poul, employs 4,396 people, headquartered in US, publicly traded since 1995.

IART stock trades at $16.62 with a market capitalization of $1.29B. The stock is valued at a price-to-earnings (P/E) ratio of -183.51, price-to-book of 1.26, price-to-sales of 0.80. Over the past 52 weeks the stock has ranged between $8.70 and $20.49, and currently trades 18.9% below its 52-week high.

On profitability, IART generates a return on equity (ROE) of -0.69%, return on capital employed of 20.25%, an operating margin of 7.53%, a net profit margin of -0.44%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1159.93 +0.28% JNJ Drug Manufacturers - General $271.19 +2.01% ABBV Drug Manufacturers - General $259.99 +1.39% MRK Drug Manufacturers - General $149.94 +1.48% UNH Medical - Healthcare Plans $396.30 +1.77% NVS Drug Manufacturers - General $161.25 +6.04% AZN Drug Manufacturers - General $162.47 +0.21% AMGN Drug Manufacturers - General $438.12 +1.92% TMO Medical - Diagnostics & Research $600.50 -2.69% NVO Biotechnology $45.12 -0.46% ABT Medical - Devices $108.97 -1.26% GILD Drug Manufacturers - General $149.92 +2.45%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides